Status:
COMPLETED
MK3207 for Treatment of Acute Migraines (3207-005)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Migraine
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.
Eligibility Criteria
Inclusion
- Men and Women from 18 to 65 years of age
- 1+ year history of migraine that typically last from 4 to 72 hours if untreated
- Had from 2 to 8 moderate or severe migraine attacks per month in the last 2 months
- Not pregnant or planning to become pregnant in next 6 months
Exclusion
- Pregnant or breast-feeding, or planning to become pregnant in next 6 months
- Cannot distinguish migraine attacks from tension type headaches
- Migraines are mild or resolve without medication in less than 2 hours
- More than 15 headache-days per month or have taken medication on more than 10 days per month in the last 3 months
- Basilar type or hemiplegic migraine headaches
- More than 50 years old when migraines began
- History of cardiovascular disorder within last 6 months
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
676 Patients enrolled
Trial Details
Trial ID
NCT00712725
Start Date
July 1 2008
End Date
January 1 2009
Last Update
February 2 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.